Halpern Financial Inc. Acquires New Stake in Eli Lilly and Company (NYSE:LLY)

Halpern Financial Inc. bought a new position in shares of Eli Lilly and Company (NYSE:LLYFree Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 400 shares of the company’s stock, valued at approximately $247,000.

A number of other institutional investors have also recently added to or reduced their stakes in LLY. Simon Quick Advisors LLC raised its holdings in shares of Eli Lilly and Company by 10.5% in the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock worth $1,706,000 after purchasing an additional 278 shares in the last quarter. Clear Harbor Asset Management LLC bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at $363,000. Liontrust Investment Partners LLP acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at $8,326,000. WASHINGTON TRUST Co boosted its stake in shares of Eli Lilly and Company by 16.5% during the 4th quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock worth $11,013,000 after acquiring an additional 2,671 shares in the last quarter. Finally, Armstrong Fleming & Moore Inc acquired a new position in shares of Eli Lilly and Company in the 2nd quarter worth $357,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 1,180 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $645.60, for a total transaction of $761,808.00. Following the transaction, the insider now directly owns 99,542,630 shares in the company, valued at $64,264,721,928. The transaction was disclosed in a filing with the SEC, which is available through this link. Over the last three months, insiders sold 195,055 shares of company stock worth $125,254,657. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Down 0.0 %

Shares of NYSE LLY opened at $777.96 on Friday. The business has a 50 day simple moving average of $737.05 and a 200 day simple moving average of $639.25. Eli Lilly and Company has a 52 week low of $334.58 and a 52 week high of $800.78. The stock has a market cap of $739.19 billion, a price-to-earnings ratio of 134.13, a PEG ratio of 1.71 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94.

Eli Lilly and Company (NYSE:LLYGet Free Report) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same period in the previous year, the company earned $2.09 earnings per share. The company’s revenue was up 28.1% compared to the same quarter last year. On average, research analysts predict that Eli Lilly and Company will post 12.42 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of recent analyst reports. Bank of America increased their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. BMO Capital Markets boosted their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $815.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, February 20th. Finally, Barclays boosted their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $689.52.

View Our Latest Analysis on LLY

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Read More

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.